23 G better than 20 G

Article

The 23-gauge system for pars plana vitrectomy offers greater postoperative comfort for the patient than does the standard 20-gauge system, according to a study published online ahead of print by the British Journal of Ophthalmology.

The 23-gauge system for pars plana vitrectomy offers greater postoperative comfort for the patient than does the standard 20-gauge system, according to a study published online ahead of print by the British Journal of Ophthalmology.

Susanne Binder, of the Department of Ophthalmology at the Rudolph Foundation Clinic, Vienna, Austria, and colleagues conducted a prospective clinical trial comparing the outcomes of pars plana vitrectomy, in which the 60 subjects were randomized into two groups using either the 23- or the 20-gauge system.

The team noted that patients operated on with 23-gauge instruments experienced less postoperative pain and required fewer conjunctival injections than the group operated on with 20-gauge instruments. In addition, the 23-gauge group had shorter opening and closing times and longer vitrectomy times than the 20-gauge group, although postop visual acuity and intraocular pressure measurements did not differ between groups. Three adverse events were noted in the 23-gauge group, compared with none in the 20-gauge group.

Despite the increased incidence of adverse events, the team concluded that postoperative patient comfort is increased by the use of 23- rather than 20-gauge instruments.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.